These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29231866)

  • 1. The Consequences of Being in an Infectious Biofilm: Microenvironmental Conditions Governing Antibiotic Tolerance.
    Sønderholm M; Bjarnsholt T; Alhede M; Kolpen M; Jensen PØ; Kühl M; Kragh KN
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of bacterial biofilms in chronic infections.
    Bjarnsholt T
    APMIS Suppl; 2013 May; (136):1-51. PubMed ID: 23635385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa biofilms in cystic fibrosis.
    Høiby N; Ciofu O; Bjarnsholt T
    Future Microbiol; 2010 Nov; 5(11):1663-74. PubMed ID: 21133688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.
    Høiby N; Krogh Johansen H; Moser C; Song Z; Ciofu O; Kharazmi A
    Microbes Infect; 2001 Jan; 3(1):23-35. PubMed ID: 11226851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.
    Ciofu O; Mandsberg LF; Wang H; Høiby N
    FEMS Immunol Med Microbiol; 2012 Jul; 65(2):215-25. PubMed ID: 22540844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung.
    Harrington NE; Sweeney E; Alav I; Allen F; Moat J; Harrison F
    J Vis Exp; 2021 Jan; (167):. PubMed ID: 33554970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.
    Jakobsen TH; Bjarnsholt T; Jensen PØ; Givskov M; Høiby N
    Future Microbiol; 2013 Jul; 8(7):901-21. PubMed ID: 23841636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microenvironmental characteristics and physiology of biofilms in chronic infections of CF patients are strongly affected by the host immune response.
    Jensen PØ; Kolpen M; Kragh KN; Kühl M
    APMIS; 2017 Apr; 125(4):276-288. PubMed ID: 28407427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Orazi G; O'Toole GA
    mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections.
    Kobayashi H
    Treat Respir Med; 2005; 4(4):241-53. PubMed ID: 16086598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.
    Hassett DJ; Cuppoletti J; Trapnell B; Lymar SV; Rowe JJ; Yoon SS; Hilliard GM; Parvatiyar K; Kamani MC; Wozniak DJ; Hwang SH; McDermott TR; Ochsner UA
    Adv Drug Deliv Rev; 2002 Dec; 54(11):1425-43. PubMed ID: 12458153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill
    Sweeney E; Sabnis A; Edwards AM; Harrison F
    Microbiology (Reading); 2020 Dec; 166(12):1171-1180. PubMed ID: 33253080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.